gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · TLSIHealthcareSurgical Instruments

TriSalus Life Sciences, Inc. Common Stock (TLSI)

$3.99+14.66%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$3.48▼ 26.11% in range
Nov 3, 2025Low $2.52 · High $7.50Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

TriSalus Life Sciences closed at $3.99 on Nov 4, up 14.66%, 46.8% below its 52-week closing high. Volume of 119.7K shares was 0.84× its 20-day average (close to normal).

Split-adjusted performance: -6.6% over one month, -12.3% over six months, -15.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $11.41M, up 1.7% from a year earlier, with a net margin of -80.5%.

Short interest was 3.4M shares at the Oct 15 settlement, up 2.9% from the prior report (8.8% of float, 20.1 days to cover).

Market cap$245.7M61.6M shares
Revenue · quarter$11.4M+1.7% YoY
Diluted EPS$-0.16—
P/E · TTM—P/S 5.5×
Net margin-80.5%Gross 86.8%
Dividend yieldNone
52-week range2.52 – 7.50−46.8% from high
Volume119.7K0.84× 20-day avg
Volatility · 60d54.8%Annualised
Short % of float8.8%20.1 days to cover
Net cash$13.2MCash $46.3M
Next earnings—Not scheduled
Split-adjusted performance
1W +1.5%1M −6.6%3M −18.1%6M −12.3%YTD −42.8%1Y −15.3%3Y −13.3%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum41
Revenue growth28
Net margin26
Value (low P/E)—
Size45

Industry medians: 6-month return −4.4%, revenue growth +8.9%, net margin −8.2%, P/E 29.7×.

Short interest

Details →
Shares short3.4M+2.9% vs prior
Days to cover20.1Settled Oct 15
% of float8.8%
Short vol. 10d58.5%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TLSITriSalus Life Sciences$3.99+14.66%−12.3%+1.7%−80.5%—$245.7M
OSUROraSure Technologies$3.66+3.68%+22.0%−1.9%20.4%—$252.4MCompare
INFUInfuSystem Holdings$13.04+1.84%+28.6%+2.6%8.7%30.4$259.6MCompare
PROFProfound Medical$7.13+2.00%−1.2%+12.3%−384.2%—$260.5MCompare
UTMDUtah Medical Products$71.74+2.46%+11.4%−14.3%31.5%21.7$227.8MCompare
ANIKAnika Therapeutics$20.32+4.47%+34.4%+15.6%10.1%—$271.9MCompare
STIMNeuronetics$2.82+24.56%+47.4%+9.1%−8.3%—$214.5MCompare
TMCITreace Medical Concepts$4.58+6.89%+137.0%−4.2%−35.0%—$297.5MCompare
NEGGNewegg Commerce$9.64+4.90%−69.7%———$202.2MCompare

News about TriSalus Life Sciences

All news →

No recent articles focused on TriSalus Life Sciences. 1 articles mention it in passing.

Quick answers

What does TriSalus Life Sciences do?
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery.
What is TLSI's market cap?
$245.68M, based on the Nov 4 close of $3.99.
Does TriSalus Life Sciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TLSI is sold short?
3.4M shares, 8.8% of float, as of Oct 15, 2026.
What sector is TLSI in?
Healthcare, in the Surgical Instruments industry.

About TriSalus Life Sciences

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

HQ: Westminster, CO102 employeesListed Aug 11, 2023trisaluslifesci.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology